Fludarabine, busulfan, and melphalan conditioning regimen in allogeneic hematopoietic stem cell transplantation for adult patients with myeloid malignancies: A multicenter retrospective study.
Article in EJHaem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors.
Jieling JiangDepartment of Hematology. Shanghai Institute of Hematology Blood & Marrow Transplantation Center Collaborative Innovation Center of Hematology Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital Shanghai China.ORCID https://orcid.org/0000-0002-0173-8459
Xiaofan LiDepartment of Hematology Fujian Medical University Union Hospital Fuzhou China.
Dong WuDepartment of Hematology Shanghai JiaoTong University Affiliated sixth People's Hospital Shanghai China.
Quanyi LuDepartment of Hematology Zhongshan Hospital Xiamen University Xiamen China.
Houcai WangShanghai Tenth People's Hospital Department of Hematology Tongji University School of Medicine Shanghai China.
Xiaoping LiDepartment of Hematology The 920th Hospital of Joint Logistics Support Force of the People's Liberation Army of China Kunming China.ORCID https://orcid.org/0000-0002-9215-9611
Yingnian ChenDepartment of Hematology The 920th Hospital of Joint Logistics Support Force of the People's Liberation Army of China Kunming China.
Yali ZhouDepartment of Hematology The 923rd Hospital of Joint Logistics Support Force of the People's Liberation Army of China Nanning China.
Guiping LiaoDepartment of Hematology The 923rd Hospital of Joint Logistics Support Force of the People's Liberation Army of China Nanning China.
Chuanhe JiangDepartment of Hematology. Shanghai Institute of Hematology Blood & Marrow Transplantation Center Collaborative Innovation Center of Hematology Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital Shanghai China.
Xiaohong YuanDepartment of Hematology Fujian Medical University Union Hospital Fuzhou China.
Youshan ZhaoDepartment of Hematology Shanghai JiaoTong University Affiliated sixth People's Hospital Shanghai China.
Chunkang ChangDepartment of Hematology Shanghai JiaoTong University Affiliated sixth People's Hospital Shanghai China.
Jie ChenDepartment of Hematology Zhongshan Hospital Xiamen University Xiamen China.
Han ZhuDepartment of Hematology The First Affiliated Hospital of Nanjing Medical University Nanjing China.
Ruye MaShanghai Tenth People's Hospital Department of Hematology Tongji University School of Medicine Shanghai China.
Nainong LiDepartment of Hematology Fujian Medical University Union Hospital Fuzhou China.
Xiaolin YinDepartment of Hematology The 923rd Hospital of Joint Logistics Support Force of the People's Liberation Army of China Nanning China.ORCID https://orcid.org/0000-0003-0500-189X
Sanbin WangDepartment of Hematology The 920th Hospital of Joint Logistics Support Force of the People's Liberation Army of China Kunming China.ORCID https://orcid.org/0000-0002-4802-0292
Jiong HuDepartment of Hematology. Shanghai Institute of Hematology Blood & Marrow Transplantation Center Collaborative Innovation Center of Hematology Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital Shanghai China.ORCID https://orcid.org/0000-0002-5613-1195
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Relapse remains the main cause of treatment failure in patients with myeloid malignancies even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We observed a particularly low incidence of relapse in patients prepared with fludarabine, busulfan and melphalan in our previous study and this multicenter retrospective analysis aimed to confirm the feasibility of the regimen and to identify the potential prognostic factors. This study was performed using registry data from adults patients with myeloid malignancies who underwent their first allo-HSCT following fludarabine(≥100 mg/m
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Fludarabine, busulfan, and melphalan conditioning regimen in allogeneic hematopoietic stem cell transplantation for adult patients with myeloid malignancies: A multicenter retrospective study. · full record | OpenQuestion